« back to Press Releases

February 21, 2021

AgeneBio Featured at Longevity Innovations and Neurodegeneration Company Showcase

HOPE4MCI Trial: First Trial Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer’s Disease with AGB101